ABSTRACT OF THE INVENTION

Disclosed are compounds having the formula:

5

$$R_3$$
 $N(H)$
 NH
 R_2
 $N(H)$
 R_1

where

$$R_1 = H$$
, C_1 - C_6 alkyl, cycloalkyl, $(CH_2)_n$ or $(CH_2)_n$ $(n=1-3)$

 $R_2 = H$, C_1 - C_6 alkyl, cycloalkyl

 $W = C_nH_{2n-m}-NH$ (n=1-6, m=0, 2, or 4),

$$R_3 = R_5$$

$$Y = R_7N$$
, -CH=CH-, R_7N -CH- or -CH-N R_7

$$\begin{split} Z &= \text{CONR}_8(\text{CH}_2)_\text{n}, \, \text{CONR}_8(\text{CH}_2)_\text{n}\text{CO}, \, \text{P(CH}_3)\text{OCHR}_8\text{OCOR}_9, \, \text{SO}_2, \\ &\text{SO}_2(\text{CH}_2)_\text{n}, \, \text{SO}_2(\text{CH}_2)_\text{n}\text{CO}, \, \text{SO}_2\text{NR}_8(\text{CH}_2)_\text{n}, \, \text{SO}_2\text{NR}_8(\text{CH}_2)_\text{n}\text{CO}, \, \text{n=1-4} \end{split}$$

 $R_4 = H$, $(CH_2)_nOH$, $(CH_2)_nOCOR_{10}$, $(CH_2)_nNR_{10}R_{11}$, $(CH_2)_nCONR_{10}R_{11}$, n=0-4

 $R_5 = H$, $(CH_2)_n NR_{12}R_{13}$, n = 0-4

 $R_6 = H$, $(CH_2)_n NR_{14}R_{15}$, n = 0-4

 $R_7 = H$, C_1 - C_6 alkyl, cycloalkyl; $R_8 = H$, C_1 - C_6 alkyl, cycloalkyl; $R_9 = H$, C_1 - C_6 alkyl, cycloalkyl; $R_{10} = H$, C_1 - C_6 alkyl, cycloalkyl; $R_{11} = H$, C_1 - C_6 alkyl, cycloalkyl; $R_{12} = H$, C_1 - C_6 alkyl, cycloalkyl; $R_{13} = H$, C_1 - C_6 alkyl, cycloalkyl; $R_{14} = H$, C_1 - C_6 alkyl, cycloalkyl; $R_{15} = H$, C_1 - C_6 alkyl, cycloalkyl

(I)

Dashed lines: optional; conformational constraint by $(CH_2)_n$, n=1-3, R' = H or O(=)

as well as pharmaceuticals compositions and methods for the treatment of opiate addiction, opiate dependence, opiate tolerance, opiate related abstinence syndrome, nicotine addition and obesity based thereon.